EGFR tyrosine kinase inhibitor erlotinib exhibits antimetastatic activity against inflammatory breast cancer

被引：0
|
作者：
Ueno, Naoto [1 ]
LaFortune, Tiffany [1 ]
Hortobagyi, Gabriel [1 ]
Lucci, Anthony [1 ]
Singh, Balraj [1 ]
Krishnamurthy, Savitri [1 ]
Esteva, Francisco [1 ]
Hung, Mien-Chie [1 ]
Zhang, Dongwei [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1767
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Effect of the EGFR tyrosine kinase inhibitor gefitinib on prostate cancer cell lines
    Limpens, J
    Van Duijn, P
    De Ridder, CMA
    Erkens, S
    Reneman, S
    Sprengers, I
    Schröder, FH
    Trapman, J
    Van Weerden, WM
    ANNALS OF ONCOLOGY, 2005, 16 : 40 - 40
  • [42] TAK-788 is a Novel and Potent Tyrosine Kinase Inhibitor with Selective Activity Against EGFR/HER2
    Chouitar, J.
    Vincent, S.
    Brake, R.
    Li, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S811 - S811
  • [43] EGFR as therapeutic target to develop new generation tyrosine kinase inhibitors against breast cancer: A critical review
    Raju, Ruby Mariam
    Joy, A. Jeffin
    Manjunathaiah, Raghavendra Nulgumnalli
    Justin, Antony
    Kumar, B. R. Prashantha
    RESULTS IN CHEMISTRY, 2024, 7
  • [44] Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib
    Oxnard, Geoffrey R.
    Janjigian, Yelena Y.
    Arcila, Maria E.
    Sima, Camelia S.
    Kass, Samantha L.
    Riely, Gregory J.
    Pao, William
    Kris, Mark G.
    Ladanyi, Marc
    Azzoli, Christopher G.
    Miller, Vincent A.
    CLINICAL CANCER RESEARCH, 2011, 17 (19) : 6322 - 6328
  • [45] Lipid Raft Localization of EGFR Alters the Response of Cancer Cells to the EGFR Tyrosine Kinase Inhibitor Gefitinib
    Irwin, Mary E.
    Mueller, Kelly L.
    Bohin, Natacha
    Ge, Yubin
    Boerner, Julie L.
    JOURNAL OF CELLULAR PHYSIOLOGY, 2011, 226 (09) : 2316 - 2328
  • [46] Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling
    Nicola Normanno
    Manuela Campiglio
    Monica R. Maiello
    Antonella De Luca
    Mario Mancino
    Marianna Gallo
    Amelia D’Alessio
    Sylvie Menard
    Breast Cancer Research and Treatment, 2008, 112 : 25 - 33
  • [47] Erlotinib induces NF-kappa B dependence that promotes EGFR tyrosine kinase inhibitor resistance in lung adenocarcinoma
    Blakely, Collin M.
    Pazarentzos, Evangelos
    Asthana, Saurabh
    Olivas, Victor
    Tan, Irena
    Fouts, Timothy
    Meshulam, Jeffrey
    Bivona, Trever G.
    CANCER RESEARCH, 2014, 74 (19)
  • [48] Skin problems and EGFR-tyrosine kinase inhibitor
    Kozuki, Toshiyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (04) : 291 - 298
  • [49] Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma
    Giroux-Leprieur, Etienne
    Dumenil, Coraline
    Chinet, Thierry
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (11) : E232 - E234
  • [50] Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinib
    Kim, JC
    Ali, MA
    Nandi, A
    Mukhopadhyay, P
    Choy, H
    Cao, C
    Saha, D
    INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS, 2005, 42 (06): : 358 - 365
12345